To compare the diagnostic and therapeutic confidence, patient outcome and costs between MRA and DSA as the initial diagnostic imaging test, in patients with symptomatic arterial disease of the leg.
INTRODUCTION
For invasive treatment planning in patients with peripheral arterial disease, visualisation of the vascular tree is necessary. The reference standard is digital subtraction angiography (DSA). As first line investigation duplex scanning (DUS) can be performed. However, DUS is time consuming and investigator dependent. The drawbacks of DSA are a compulsory admission, as well as risk of complications like contrast allergy or renal toxicity. CTA or MRA are less invasive alternatives and both have been evaluated in diagnostic research.
Contrast enhanced MRA (CE MRA) has been proven a reliable technique with an adequate diagnostic performance to replace DSA, described in individual studies as well in meta-analysis. [1] [2] [3] [4] [5] [6] Drawbacks of MRA are less optimal imaging of distal arteries 7,8 or overestimation of stenoses. 9 Onegroupwasable to detect more patent distal arteries. 10 To avoid venous over projection of the crural vessels in order to visualize more patent arteries, the scanning protocol had been changed performing the imaging from distal to proximal. 11 MRA proved to be a reliable method for making a treatment plan. 12, 13 However, in published series as well as in our own experience, 7 to 10% of the patients need additional diagnostic work up after MRA.12 All previous studies have to be classified as diagnostic research: both MRA and DSA were evaluated on the same patient, and compared with the treatment plan. There is no literature about evaluation of clinical utility and patient outcomes observed when performing MRA instead of DSA in daily practice.
The purpose of our study was to prospectively compare the diagnostic and therapeutic confidence, the patient outcome (in terms of treatment) and costs between MRA and DSA as the initial diagnostic imaging test in patients with symptomatic arterial disease of the leg. We performed a diagnostic trial where the imaging was part of the treatment.
MATERIAL AND METHODS

PATIENTS
Between November 2004 and November 2006, we approached all eligible patients from the department of vascular surgery. Baseline characteristics were collected for each patient with symptomatic arterial disease (ankle-brachial index of less than 0.90) and were referred for a diagnostic imaging work-up to evaluate the feasibility of a revascularisation procedure. Patients had either severe disabling intermittent claudication (Fontaine classification IIb) or critical ischemia according to the SVS/ISCVS criteria (Fontaine classification III or IV). 14 Excluded were patients with acute ischemia and contra-indications for MRA or DSA: Kreatinine > 170 mmol/l, claustrophobia, metal clips in vital organs and pacemakers. Primary endpoints were patient satisfaction and necessity for additional imaging. Secondary endpoints were treatment plan, types of treatment (conservative, angioplasty, surgery) and costs. The study was approved by the hospital institutional review board (WO 03.070) and informed consent was obtained from all patients.
The study was performed according to Good Clinical Practice guidelines. 15 Data are analyzed and reported in accordance with the guidelines of the Consolidated Standards of Reporting Trials. 16
Fig. 1 Flowchart of eligible and included patients
STUDY DESIGN
Patients were randomly allocated to either MRA as diagnostic strategy, or DSA. A non-stratified computer-generated randomization sequence was made. The allocation sequence was concealed by means of sealed opaque consecutively numbered envelopes. Patients were enrolled by the vascular surgeons, who were unaware of the randomization sequence. Imaging techniques Imaging was performed on a 1.5 Tesla MR system (Philips Gyroscan Intera T15-N release 8.1.1;
Philips Medical Systems, Best, the Netherlands). Patients were placed in the supine position and entered into the magnet with their feet first. The lower legs were immobilized and placed into the surface coil. Axial TOF views were used to plan the subsequent image volumes for the ce-MRA scan at the three stations: aortoiliacal, femoral and crural station (TR (ms)/TE (ms) 6.9/11.6, flip angle 50 degrees, field of view (FOV) 430 x 100 mm 2 , matrix 256 x 256 mm 2 ). The Acquisition of the contrast enhanced images were performed with a fast 3D spoiled gradientecho sequence (T1-FFE/M; TR=6.0; TE=1.52; flip angle=35, FOV=430 mm, no flow compensation). The standard quadrature body coil was used for signal transmission and reception. Non-enhanced 3D data sets were obtained for each station and later subtracted from the identical contrast-enhanced data sets to increase vessel to background noise.
Images were acquired in the coronal plane and the number of slices and imaging parameters were for all the 3 stacks identical: 70 slices of 1.5 mm. The actually measured partition thickness was 3 mm and later interpolated to 1.5 mm. In-plane resolution was 0.84 x 0.84 x 1.5 mm 3 . The maximum total coverage in the feet head direction was 126 cm. To ensure that all arteries were included in the FOV, we used a 30-mm overlap between consecutive stations. The scan time of the individual stacks was 28.3 sec. Table movement was scanner controlled and the time between 2 consecutive scans was approximately 5 seconds. For all patients a dedicated peripheral surface coil was used at the crural station (Synergy Body Coil, 4 elements, Philips medical system).
A paramagnetic contrast agent (0.4 ml Gd/kg bodyweight, Gadodiamine 0.5 M [ Omniscan ® , Nycomed]) was injected per patient to enhance intravascular signal. The body-weight-adjusted dose was diluted with 0.9% saline to a total standard scan volume of 33 ml contrast medium solution. Those patients of over 82.5 kg in whom the total amount of the body-weight-adjusted dose exceeded 33 ml of contrast agent were also maximized to the standard scan volume of 33 ml. Contrast medium was administered as a single continuous bolus in an antecubital vein at a rate of 1.0 ml/sec for the first 10 ml, followed by a rate of 0.2 ml/sec for the next 20 ml of contrast. Immediately after injection of contrast material, 20 ml of normal saline was administered at a flow rate of 0.2 ml/sec to flush tubing and veins. All injections were done using a remote controlled MR compatible injection system (Medrad Spectris, Pittsburgh, PA).
To minimize venous enhancement, the ce-MRA images were first obtained at the crural station, and subsequently at the femoral and aortoiliacal station, scanning a feet-to-head direction. The start of the scan at the crural station was based on the determination of the arrival time of contrast material at the femoral station of the symptomatic extremity of interest indicated by the ordering vascular surgeon. According to our experience, real time detection of the bolus arrival is too difficult to establish in the severely diseased and smaller arteries of the crural station. A 3 ml undiluted contrast agent test bolus was injected at a rate of 5 ml/sec and monitored at the femoral station using real time bolus monitoring software (Bolus-Trak, Philips Medical Systems).
The scan delay of the crural station was then calculated by the arrival time at the femoral station and a standard 25 seconds was added for all patients allowing contrast material to reach the ankle (scan delay ¼ femoral arrival time þ 25 seconds). After completion of the feet-tohead scan an additional scan of the crural station was performed supplying dynamic information. 
MEASUREMENT OF CLINICAL UTILITY AND PATIENTS OUTCOMES
We assessed the treatment plan during the weekly vascular conference, where therapeutic decisions were made in consensus. Sometimes, when indicated, an angioplasty was performed during the DSA session in consensus between the radiologist and the vascular surgeon on call. Furthermore, when it was not possible to make a definitive treatment plan recommendations for additional imaging were measured. The patient confidence was measured by a Preference Scale (PS). 17 In the PS the patient is asked how the diagnostic investigation was experienced on a 4 or 5 point scale for items like: pain during the imaging, claustrophobia, noisiness, length of investigation, inactivation due to the investigation, willingness to undergo the imaging again.
Non-responding patients were contacted by telephone to obtain as much complete data as possible. * In the MRA group there were significant more symptomatic right legs and in the DSA group more symptomatic left legs (table 1) . ¶ no intervention means conservative treatment (=walking exercise) for a symptomatic leg as well as no treatment for an asymptomatic leg.
STATISTICAL ANALYSIS
The required sample size was estimated on the basis of the primary outcome measure, which was the patients' preference for a certain diagnostic work up, assuming that kinds of treatments and treatment outcomes were equal. 17 We assumed that the difference in patient satisfaction would be 15%: 95% in the MRA group compared to 80% in the DSA group. 17 With a power of 90% and an alpha level of 5%, we would require at least 99 patients in each group.
The results were analyzed according to the intention-to-treat principle. Continuous variables with normal distributions (expressed as means ± SD) were compared with the use of an unpaired Student's t-tests. The c2 test was used for dichotomous and categorical outcomes and the Mann-Whitney test for non-parametric outcomes. The relative risk (RR) was calculated with 95% confidence intervals (95% CI). In addition the differences adjusted for predictive baseline characteristics were analyzed by using multivariate multiple logistic regression analysis. It was assumed that the severity of the disease (Fontaine classification), cardiac disease and diabetes mellitus were potentially predictive for outcome. For all outcome measures a p-value of less than 0.05 indicated a statistical significant difference. Calculations were performed with SPSS 14.0 for Windows (SPSS, Chicago, Ill).
RESULTS
PATIENT ENROLLMENT
A total of 391 patients were assessed for eligibility ( Fig. 1) . We planned to enroll 200 patients, however 97 patients were assigned to undergo MRA and 100 were assigned to undergo DSA.
Three randomization numbers were lost: in one case the envelope with a randomization number (DSA) was lost and 2 patients were included twice (both times second randomization in the DSA group). The first randomization was included in the analysis (once MRA and once DSA). In one patient, included for MRA, a DSA was performed. In the DSA group there were more patients with diabetes and vascular disease of the left leg (Table 1) . Nine patients did not undergo any imaging modality for various reasons. Therefore data of 188 patients were available for the primary outcome: in the MRA group 91 patients compared to 97 patients in the DSA group. 
CLINICAL UTILITY AND PATIENT OUTCOMES
In the MRA group in 11% of patients additional diagnostic work up was performed compared to 10% in the DSA group: p = 0.5 ( Table 2) . Treatment plans as well as the ultimate treatment were not statistically significant different in both groups of patients. In detail, in 120 symptomatic right legs 78 interventions were planned (65%) and in 95 of 136 symptomatic left legs (70%). The reasons for a different treatment from the treatment plan did not differ between the two groups.
With adjustment for unbalanced baselines scores and potential interaction between subgroups of patients (diabetes, cardiac disease, sex, Fontaine classification and ankle-brachial index) we found no statistically significant differences in outcome for MRA compared to DSA in terms of treatment plans, treatment and necessity for additional imaging. With Fontaine II additional imaging was performed in 8 patients in the MRA group, compared to 7 in the DSA group. With
Fontaine III and IV these numbers are 3 patients in both groups: adjusted Odds Ratio 1.8 (95% CI 0.2-13.4). The response for the PS list was 60% in the MRA group compared to 58% in the DSA group.
84% of the patients in the MRA group judged the diagnostic work up as comfortable compared to 57% in the DSA group: p = 0.013 ( Table 3) .
75% of the patients in the MRA group compared tot 40% of the patients in the DSA group were willing to undergo the imaging again: p = 0.008 (Table 4 ). Patients in the MRA group experienced less pain but the imaging was more noisiness (p = 0.010) ( Table 5 ). There were 9 complications in the MRA group (groin hematoma after angioplasty (n = 3), cerebral infarction (n=1), dissection after angioplasty (n=1) and death (n=4: before imaging n=2 and per procedural n=2) compared to 6 in the DSA group (cerebral infarction (n=1), dissection after angioplasty (n=1), in stent thrombosis (n=1), myocardial infarction (n=1) and death (n=2). Table 6 shows the outcomes and treatment during 4 months after randomization. In 134 patients one or more vascular interventions were performed in one or both legs and 53 patients were treated conservatively. Six more patients died during follow up: MRA (n=3); DSA (n=3). and 39 patients in the MRA compared to 36 patients in the DSA group underwent angioplasty ( Table 6 ). The mean total in hospital costs (including imaging) during the first 4 months were €4768 in the MRA group compared to €4697 in the DSA group (Table 7) . 
FOLLOW UP AND COSTS
DISCUSSION
A randomized controlled diagnostic trial was performed to evaluate the clinical utility, patient outcomes and costs of 2 diagnostic strategies: MRA compared to the reference standard DSA.
Patients experienced that MRA was more comfortable and less painful. There was no statistically significant difference in ability to make a treatment plan, need for additional diagnostic work up, kinds and amount of invasive procedures which were performed during 4 month of follow up.
The results suggest that MRA might replace DSA as the initial diagnostic modality in the diagnostic work up in patients with peripheral arterial disease. From meta-analysis of 34 studies in 1090 patients it was concluded that MRA is highly accurate for the assessment of the entire lower extremity for arterial disease, compared to the reference standard: DSA.2 Three dimensional CE-MRA proved to be superior to 2-DMRAwith an estimated point of equal sensitivity and specificity of 94%. More recent studies, with ongoing experience, the MRA performed even better with a diagnostic accuracy of more than 95%. 18, 19 However, technical problems with MRA can occur in 14% of cases, of whom venous over projection in the crural segment is the most disturbing. This may lead in 6% of the patients to additional imaging. 20 Our patients judged the MRA as more comfortable compared to the DSA. Likewise, in a study with 30 patients were both MRA and DSA were performed in each case, patients experienced the MRA as more comfortable. 17 Patients who had both diagnostic modalities experienced limitations on daily activities and physical function. This was not the case in our patients. Our patients had more pain during the DSA. This is in contrast with a study in which the patients scored the same pain category during MRA and DSA. 17 Our MRA patients were willing to undergo the procedure again. This is in line with the literature where both diagnostic modalities were performed in the same patients. Patients were willing to pay 2.12% of annual income to avoid MRA compared to 7.41% for DSA. The differences of both outcomes were statistically significant. 17 Our study proved that for both imaging techniques the necessity for additional imaging to make a treatment plan is not statistically significant different. In 90% of the patients the initial imaging is conclusive to make a treatment plan. In another study additional DSA, after MRA, was judged to be necessary in 33% of the cases. 21 In another diagnostic trial it was necessary to perform additional imaging in 17% of the cases after an initial MRA imaging during a 6 months follow up. 22
Additional imaging in our study was less frequent. Mostly, we had to perform additional DUS in order to evaluate a possible stenosis, suggested on MRA as well as on DSA. Venous contamination can be a problem in up to 5% of the cases and was minimalized by adapting the protocol. 11, 20 In this way MRA proved to be able of identifying more patent crural vessels, compared to DSA. 23 MRA has some limitations. There is a contraindication in patients with some form of metal (e.g. pacemaker) in their body. Also intra arterial stents cause artifacts. This can be the reason for additional imaging. Claustrophobia can be a contra-indication and is reported in up to 12% of the cases. 21 The alternative can be another minimal invasive technique like the CTA. The interobserver agreement in CTA is slightly less than for MRA: Kappa 0.85 compared to 0.90 for all segments. 22 Calcifications, especially in the crural segments, can cause problems with interpretation. In a diagnostic trial it was concluded that the physicians confidence in making a correct therapeutic choice was significantly lower in CTA compared to DSA. 24 However, considering the equal quality of live in both treatment arms and that CTA as initial diagnostic imaging was significantly cheaper, it was concluded that CTA provides sufficient information for therapeutic decision making. In another trial CTA and MRA proved to be equal, where only the mean costs of diagnostic imaging was slightly higher. 22
Striking is the fact that, despite the indication for the diagnostic imaging not all patients had invasive treatment. The main reason is that the balance between the vascular complaints and the possible treatment options, considering the patients condition and co-morbidity, was unfavorable in some cases. 21 Our results are in line with other studies were the percentages vary between 56% and 71%. 21, 22, 24 There were limitations in our study. The evaluation of the imaging, making the treatment plan and the treatment were not blinded. Patients were known by the physicians and treatment plans were in accordance with patient's condition and wishes. There were differences in baseline characteristics. Despite these differences, the conclusion of our study did not alter after adjustment for these variables. Cost calculations are from hospital perspective and not from social perspective. The treatments were not different, so we don't expect differences in these patients of whom the most are retired from active participation in work process.
In conclusion, an adequate treatment plan can be made with MRA in patients with peripheral arterial disease of the leg. This diagnostic modality is experienced as more comfortable and less painful compared to DSA, with a trend of a better quality of life 4 months after randomization.
Total treatment costs and clinical outcomes of both modalities are comparable. 
